1. Home
  2. RUM vs NVAX Comparison

RUM vs NVAX Comparison

Compare RUM & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc.

RUM

Rumble Inc.

HOLD

Current Price

$7.06

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.59

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUM
NVAX
Founded
2013
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.3B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
RUM
NVAX
Price
$7.06
$9.59
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
4.4M
4.9M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
80.72
309.76
EPS
N/A
N/A
Revenue
$100,622,320.00
$1,123,479,000.00
Revenue This Year
$209.98
N/A
Revenue Next Year
$40.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.38
64.69
52 Week Low
$4.62
$6.20
52 Week High
$10.60
$11.85

Technical Indicators

Market Signals
Indicator
RUM
NVAX
Relative Strength Index (RSI) 42.51 53.12
Support Level $6.52 $9.14
Resistance Level $7.89 $10.26
Average True Range (ATR) 0.69 0.63
MACD -0.25 0.03
Stochastic Oscillator 6.07 42.78

Price Performance

Historical Comparison
RUM
NVAX

About RUM Rumble Inc.

RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: